Showing 5001-5010 of 7243 results for "".
- Taylor Fritz Partners with La Roche-Posay for Sun Safety Campaignhttps://practicaldermatology.com/news/taylor-fritz-partners-la-roche-posay-sun-safety-campaign/2467419/La Roche-Posay has partnered with professional tennis player Taylor Fritz to promote awareness of sun safety practices, according to a news release. Taylor Fritz, currently the highest-ranked American male tennis player, will serve as the sun safety spokesperson for La Roche-Posay to high
- Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeuticshttps://practicaldermatology.com/news/Johnson-johnson-completes-acquisition-yellow-jersey-therapeutics/2467362/Johnson & Johnson has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics, to secure the global rights to NM26, a novel, investigational first-in-class bispecific antibody being evaluated for the treatment of atopic dermatitis
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- England's NICE Recommends Lebrikizumab for Moderate-to-Severe ADhttps://practicaldermatology.com/news/englands-nice-recommends-lebrikizumab-moderate-severe-ad/2467289/England’s National Institute for Health and Care Excellence (NICE) has recommended lebrikizumab for use in treating moderate-to-severe atopic dermatitis, Almirall S.A. announced in a press release. Lebrikizumab, sold by Almirall under the brand name Ebglyss, is indicated for the treatment
- NICE Recommends Ebglyss (lebrikizumab) for Use in Moderate to Severe AD in the NHS Englandhttps://practicaldermatology.com/news/nice-recommends-ebglyss-lebrikizumab-use-moderate-severe-ad-nhs-england/2467288/Almirall announced that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe atopic dermatitis in the NHS England. Lebrikizumab is indicated for the treatment of adult and adolescent patients (12 years and older
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Study: 5-mm Margins Adequate for Small Melanoma in Situ Lesionshttps://practicaldermatology.com/news/study-5-mm-margins-adequate-small-mis-lesions/2467262/New research shed light on the recurrence rates of melanoma in situ (MIS) lesions removed with a 5-mm margin. "The incidence of MIS has increased significantly over the past decades, and traditional guidelines for treatment of MIS have been excision with a 5-mm clinical margin; however, c
- Survey: Just 40% See Dermatologists Annually Despite Skin Concernshttps://practicaldermatology.com/news/survey-just-40-see-dermatologists-annually-despite-skin-concerns/2467226/Manufacturer CeraVe has announced findings from a new survey suggesting that while 80% of participants experienced skin concerns, just 40% of them visited a dermatologist for an annual skin exam. The survey of 1,000 American adults also revealed that 25% suffered from serious skin condit
- Dermavant Receives Approval of Tapinarof for Psoriasis and Atopic Dermatitis in Japanhttps://practicaldermatology.com/news/dermavant-receives-approval-tapinarof-psoriasis-and-atopic-dermatitis-japan/2467170/Dermavant Sciences announced that Japan Tobacco has received approval in Japan for tapinarof c
- Study: Oral Minoxidil Not Superior to Topical Minoxidilhttps://practicaldermatology.com/news/non-oral-and-topical-minoxidil/2467152/Daily oral minoxidil, 5 mg was not superior to topical minoxidil, 5%, in a population of male patients with alopecia according to a new study in JAMA Dermatology. "There has been increased interest in low-dose oral minoxidil for androgenetic alopecia (AGA) treatment," the autho